Showing 135 results
-
Viewpoint
Maximizing the Power of Real-world Evidence (RWE): AI’s Role in Accelerating Life Sciences' Next Era
June 12, 2025Life sciences enterprises are increasingly turning to Real-world Evidence (RWE) as an essential input for decision-making across the product life cycle – from early-stage R&D to post-market access and safety. RWE offers validated insights into treatment effectiveness, patient outcomes, and safety, but fragmented data sources, inconsistent quality, and evolving compliance expectations often challenge its generation. With the rising volume and diversity of Real-world Data (RWD), traditional analytics approaches are no longer sufficient. AI, including technologies such as NLP, machine learning, and generative models, is redefining how RWE is produced and operationalized. AI is accelerating data curation, enabling predictive analytics, and delivering regulatory-grade evidence at scale. This Viewpoint outlines how AI is transforming the RWE landscape across six domains: drug discovery, clinical trials, manufacturing, commercialization, pharmacovigilance, and regulatory affairs. It also explores emerging models such as insights-as-a-service and autonomous evidence networks, which offer scalable, modular engagement approaches for AI-powered RWE. The report provides practical recommendations for both enterprises and providers, covering capability investments, infrastructure modernization, governance models, and partnership strategies. It aims to help stakeholders reimagine their data-to-evidence journeys and build future-ready ecosystems for continuous, AI-enabled insight generation. Scope Industry: life sciences Geography: global Contents In this report, we examine: RWE’s current landscape and growing importance in life sciences AI’s role in addressing foundational RWE challenges AI-enabled key RWD/RWE use cases across the product life cycle Emerging engagement models such as BPaaS, AaaS, and IaaS Future-forward models, including autonomous evidence networks and modular AI-enabled partnerships Strategic considerations to operationalize AI-powered RWE for enterprises and providers
-
June 10, 2025Life sciences enterprises are under increasing pressure to accelerate innovation, optimize costs, and embrace emerging technologies like AI. These priorities are reshaping how and where organizations source capabilities, prompting a fresh look at the roles of Global Capability Centers (GCCs) and service providers. GCCs are gaining renewed focus as enterprises invest in internal talent and domain expertise, while service providers continue to play a critical role in delivering flexibility, scale, and specialized capabilities. However, very few conversations bring both sides of the sourcing story to the table. Watch Everest Group’s experts as they explored how life sciences sourcing strategies are evolving in an AI-first world and where enterprises are choosing to build vs. buy capabilities. What questions did the webinar answer? How are life sciences enterprise priorities changing, and what is the impact on the sourcing strategy? What capabilities are companies increasingly looking to bring in-house through GCCs, and which are they turning to service providers to deliver? In an AI-first world, how is the value proposition evolving for both models?
-
June 09, 2025The life sciences industry is undergoing rapid digital transformation, fueled by the need for greater agility, regulatory compliance, and patient-centric operations. Enterprise platforms such as SAP, Oracle, and Salesforce have evolved from back-end systems of record to strategic innovation enablers, powering R&D, strengthening supply chains, and enhancing commercial effectiveness. However, challenges remain, as many organizations still operate fragmented legacy systems, struggle with complex migrations, and navigate the trade-offs between global standardization and local compliance. To address these needs, providers are investing in industry-specific accelerators, compliance-ready architectures, and intelligent automation capabilities. They are strengthening their expertise across SAP, Oracle, and Salesforce platforms, while also expanding AI/ML offerings to drive more proactive, insights-led operations. In this report, we assess 20 life sciences enterprise platform providers and position them on Everest Group’s PEAK Matrix®, a composite index of distinct metrics related to the providers’ capabilities and market impact. The study will enable buyers to choose the best-fit provider based on their sourcing considerations, while providers will be able to benchmark their performances against each other. Scope Industry: life sciences Geography: global Services: life sciences enterprise platform services Contents In this report, we examine: The provider landscape for life sciences enterprise platform services Life sciences enterprise platform providers on several capabilities and market success-related dimensions
-
June 03, 2025As life sciences enterprises navigate the clinical development’s growing complexity due to advanced therapies, increased data volumes, and the need for operational agility, outsourcing models are evolving in response. Sponsors now seek flexible, cost-efficient, and expertise-driven models to accelerate time-to-market and maintain regulatory compliance. This Viewpoint examines core characteristics, market shifts, and strategic implications of Full-service Outsourcing (FSO) and Functional Service Provider (FSP) models in clinical operations. Sponsors can benefit from tailored insights to assess and refine their clinical outsourcing strategy. The report explores the increasing adoption of hybrid models, the rising influence of AI and cloud-based infrastructures, and key decision-making factors, such as therapeutic complexity and trial geography. It highlights how enterprises can unlock greater control, scalability, and innovation in clinical trials by selecting the right outsourcing mix. It empowers decision-makers with strategic insights to navigate evolving outsourcing models, enabling them to enhance operational agility, optimize costs, and maintain greater oversight. Scope Industry: life sciences Geography: global Contents In this report, we examine FSO and FSP outsourcing models’ features and use cases Market trends influencing the shift in outsourcing approaches Key decision-making factors for selecting the right model Challenges in implementing and optimizing outsourcing strategies The growing relevance and advantages of hybrid models in clinical operations
-
June 02, 2025Life sciences enterprises are embracing digital technologies to navigate the growing complexities in drug development, commercialization, and regulatory compliance. As economic pressures and competitive dynamics intensify, organizations are turning to digital services to improve operational resilience and achieve faster time-to-market. Providers are responding with targeted investments in AI / generative AI, data platforms, and industry-specific solutions to meet enterprise demands across the life sciences value chain. This PEAK Matrix® report offers a detailed evaluation of 35 providers delivering digital services in the life sciences sector, including biopharmaceutical, medical device, and others. It examines how these providers are enabling transformation through scalable solutions, co-innovation models, and differentiated capabilities. By assessing providers across dimensions such as market adoption, innovation, and delivery footprint, the report helps enterprise buyers identify the right strategic partners for their digital agendas. Scope Industry: life sciences (biopharmaceutical, medical devices, and others) Service: digital services Geography: global Contents In this report, we offer: Providers’ evaluations The evaluation scope Market trends Provider landscape analysis Key buyer considerations and takeaways Memberships Life Sciences Information Technology Sourcing and Vendor Management
-
April 30, 2025These Discoveries are available only to Advanced SciTech members. For information on membership, please contact us Discoveries focus on specific science and technology innovations that address today’s critical business issues and challenges. These brief yet detailed profiles highlight innovations across the world's leading companies, start-ups, universities, institutes, and the entire R&D ecosystem and leverage the Strengths, Opportunities, Aspirations, and Results (SOAR) framework to analyze the innovations’ rationale and possible benefits. The insights will help you understand the themes shaping science and technology development, enhance your R&D, strengthen strategies, comprehend the developer landscape, and identify best practices for your product pipelines.
-
April 03, 2025Pharmacovigilance (PV) has evolved into a strategic imperative, driven by intensified regulatory scrutiny and an increasing focus on patient safety. Pharmaceutical companies now face a rapidly evolving landscape characterized by rising adverse event volumes, fragmented real-world data sources, and increasingly complex global regulatory frameworks. Regional variations in drug safety reporting requirements further compound compliance challenges across diverse markets. At the same time, the demand for timely and accurate reporting has intensified, particularly as next-generation technologies introduce operational efficiencies while simultaneously raising regulatory concerns regarding the ethical and compliance implications of generative AI in PV. To navigate these complexities, external providers have become indispensable partners, offering deep PV expertise and adaptable support models. These providers bring proven drug safety process frameworks, highly trained PV professionals, and localized regulatory expertise, including qualified persons for PV, ensuring seamless compliance across global markets. Recognizing the need for enhanced efficiency, providers are investing in AI, automation, and advanced analytics to optimize case processing, adverse event management, and signal detection, all while reducing costs and improving operational scalability. In this report, we assess 29 PV operations providers featured on the Pharmacovigilance (PV) Operations PEAK Matrix®. Each provider profile provides a holistic picture of its service focus, solution offerings, and domain investments. The assessment is based on Everest Group’s annual RFI process for calendar year 2024, interactions with leading PV providers, client reference checks, and an ongoing analysis of the PV operations market. Scope Industry: life sciences Geography: global The assessment is based on Everest Group’s annual RFI process for calendar year 2024, interactions with leading PV providers, client reference checks, and ongoing analysis of the PV market Contents This report analyzes 29 providers in detail and includes: Their relative positioning on Everest Group’s Pre-approval Pharmacovigilance (PV) Operations PEAK Matrix® Their relative positioning on Everest Group’s Post-approval Pharmacovigilance (PV) Operations PEAK Matrix® A comparison of their capabilities and market shares Their strengths and limitations
-
March 28, 2025These Discoveries are available only to Advanced SciTech members. For information on membership, please contact us Discoveries focus on specific science and technology innovations that address today’s critical business issues and challenges. These brief yet detailed profiles highlight innovations across the world's leading companies, start-ups, universities, institutes, and the entire R&D ecosystem and leverage the Strengths, Opportunities, Aspirations, and Results (SOAR) framework to analyze the innovations’ rationale and possible benefits. The insights will help you understand the themes shaping science and technology development, enhance your R&D, strengthen strategies, comprehend the developer landscape, and identify best practices for your product pipelines.
-
Feb. 28, 2025These Discoveries are available only to Advanced SciTech members. For information on membership, please contact us Discoveries focus on specific science and technology innovations that address today’s critical business issues and challenges. These brief yet detailed profiles highlight innovations across the world's leading companies, start-ups, universities, institutes, and the entire R&D ecosystem and leverage the Strengths, Opportunities, Aspirations, and Results (SOAR) framework to analyze the innovations’ rationale and possible benefits. The insights will help you understand the themes shaping science and technology development, enhance your R&D, strengthen strategies, comprehend the developer landscape, and identify best practices for your product pipelines. Membership(s) Advanced SciTech
-
Provider Compendium
Life Sciences Clinical Data and Analytics (D&A) Platforms – Provider Compendium 2025
Feb. 28, 2025Decentralized and hybrid designs add more complexity to clinical trials, generating vast data volumes from diverse sources. This complexity creates significant data management challenges. In response, sponsors are adopting unified clinical Data and Analytics (D&A) platforms to centralize and standardize clinical data for actionable insights, offering real-time monitoring, predictive analytics, and risk management. These platforms transform disparate datasets into cohesive, structured formats, helping stakeholders detect outliers, predict adverse events, and generate on-demand dashboards and reports. D&A platforms offer centralized repositories, Risk-based Quality Management (RBQM), and seamless integration with Electronic Health Records (EHRs), wearables, and medical devices. These features improve data access and interoperability, contributing to more informed decision-making and enhanced quality and risk oversight. To meet sponsor needs, clinical D&A platform providers are integrating AI and generative AI to automate repetitive tasks, generate insights, and strengthen quality and risk management. In this report, we analyze 18 clinical D&A platform providers’ capabilities and offerings. The report empowers buyers to select the right provider for their sourcing considerations and enables providers to benchmark themselves against their competition. Scope Industry: life sciences Geography: global Contents In this report, we: Examine the clinical D&A platform provider landscape Assess clinical D&A platform providers on their capabilities and market success-related dimensions Membership(s) Clinical Development Technology Sourcing and Vendor Management
